Skip to main content
main-content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Health Services Research 1/2017

Avoidable costs of stenting for aortic coarctation in the United Kingdom: an economic model

Zeitschrift:
BMC Health Services Research > Ausgabe 1/2017
Autoren:
Maximilian Salcher, Alistair Mcguire, Vivek Muthurangu, Marcus Kelm, Titus Kuehne, Huseyin Naci, CARDIOPROOF
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12913-017-2215-2) contains supplementary material, which is available to authorized users.

Abstract

Background

Undesirable outcomes in health care are associated with patient harm and substantial excess costs. Coarctation of the aorta (CoA), one of the most common congenital heart diseases, can be repaired with stenting but requires monitoring and subsequent interventions to detect and treat disease recurrence and aortic wall injuries. Avoidable costs associated with stenting in patients with CoA are unknown.

Methods

We developed an economic model to calculate potentially avoidable costs in stenting treatment of CoA in the United Kingdom over 5 years. We calculated baseline costs for the intervention and potentially avoidable complications and follow-up interventions and compared these to the costs in hypothetical scenarios with improved treatment effectiveness and complication rates.

Results

Baseline costs were £16 688 ($25 182) per patient. Avoidable costs ranged from £137 ($207) per patient in a scenario assuming a 10% reduction in aortic wall injuries and reinterventions at follow-up, to £1627 ($2455) in a Best-case scenario with 100% treatment success and no complications. Overall costs in the Best-case scenario were 90.2% of overall costs at Baseline. Reintervention rate at follow-up was identified as most influential lever for overall costs. Probabilistic sensitivity analysis showed a considerable degree of uncertainty for avoidable costs with widely overlapping 95% confidence intervals.

Conclusions

Significant improvements in the treatment effectiveness and reductions in complication rates are required to realize discernible cost savings. Up to 10% of total baseline costs could be avoided in the best-case scenario. This highlights the need to pursue patient-specific treatment approaches which promise optimal outcomes.
Zusatzmaterial
Additional file 1: The supplemental material provides additional information on model inputs and results of the extensive sensitivity analyses conducted. The supplemental material is provided in one document under the following section headings: A1. Results of probabilistic sensitivity analysis. A2. Calculation of cost inputs and standard deviations. A3. Univariate sensitivity analyses of all input parameters. (PDF 1.14 mb)
12913_2017_2215_MOESM1_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Health Services Research 1/2017 Zur Ausgabe